Peripheral T cell lymphoma: clinical utility of romidepsin

References

• Jaffe ES, Harris NL, Stein H, et al. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood, 2008;112(12):4384–4399.
   PubMed Web of Science ®Google Scholar
• Rizvi MA, Evens AM, Tallman MS, et al. T-cell non-Hodgkin lymphoma. Blood. 2006;107(4):1255–1264.
   PubMed Web of Science ®Google Scholar
• Vose J, Armitage J, and Weisenburger D, et al. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–4130.
   PubMed Web of Science ®Google Scholar
• Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768–3785.
   PubMed Web of Science ®Google Scholar
• Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol. 2005;23(17):3971–3993.
   PubMed Web of Science ®Google Scholar
• Bereshchenko OR, Gu W and Dalla-Favera R, et al. Acetylation inactivates the transcriptional repressor BCL6. Nat Genet. 2002;32(4):606–613.
   PubMed Web of Science ®Google Scholar
• Bates SE. Epigenetic therapies reach main street. Clin Cancer Res. 2009;15(12):3917.
   Web of Science ®Google Scholar
• Davie JR. Covalent modifications of histones: expression from chromatin templates. Curr Opin Genet Dev. 1998;8(2):173–178.
   PubMed Web of Science ®Google Scholar
• Cotto M, Cabanillas F, Tirado M, et al. Epigenetic therapy of lymphoma using histone deacetylase inhibitors. Clin Transl Oncol. 2010;12(6):401–409.
   PubMed Web of Science ®Google Scholar
• Bolden JE, Peart MJ, and Johnstone RW Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5(9):769–784.
   PubMed Web of Science ®Google Scholar
• Batty N, Malouf GG, Issa JP. Histone deacetylase inhibitors as antineoplastic agents. Cancer Lett. 2009;280(2):192–200.
   PubMed Web of Science ®Google Scholar
• Ashkenazi A. Targeting death and decoy receptors of the tumour- necrosis factor superfamily. Nat Rev Cancer. 2002;2(6):420–430.
   PubMed Web of Science ®Google Scholar
• Chen Z, Clark S, Birkeland M, et al. Induction and superinduction of growth arrest and DNA damage gene 45 (GADD45) alpha and beta messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells. Cancer Lett. 2002;188(1–2):127–40.
   Web of Science ®Google Scholar
• Olsen EA, Kim YH, Kuzel TM, et al. Phase Ilb multicenter trial of vor- inostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(21):3109–3115.
   PubMed Web of Science ®Google Scholar
• Demierre M. Pooled analysis of two international multicenter clinical studies of romidepsin in 167 patients wiht cutaneous lymphoma. 45 th American Society of Clinical Oncology Annual Meeting, 2009.
   Google Scholar
• Coiffier B, Pro B,Prince HM, et al. Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy. J Clin Oncol. 2012;30(6):631–636. Epub 2012 Jan 23.
   PubMed Web of Science ®Google Scholar
• Piekarz RL,Robey R, Sandor V, et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood. 2001;98(9):2865–2868.
   PubMed Web of Science ®Google Scholar
• Ueda H, Manda T, Matusmoto S, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J Antibiot (Tokyo), 1994;47(3):315–323.
   PubMed Web of Science ®Google Scholar
• Nakajima H, Kim YB, Terano H, et al. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res. 1998;241(1):126–133.
   PubMed Web of Science ®Google Scholar
• Ueda H, Nakajima H, Hori Y, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo). 1994;47(3):301–310.
   PubMed Web of Science ®Google Scholar
• Furumai R, Matsuyama A, Kobashi N, et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 2002;62(17):4916–4921.
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Bates SE. Epigenetic modifiers: basic understanding and clinical development. Clin Cancer Res. 2009;15(12):3918–3926.
   PubMed Web of Science ®Google Scholar
• Fouladi M, Furman WL, Chin T, et al. Children’s Oncology Group. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children’s Oncology Group report. J Clin Oncol. 2006;24(22):3678–3685.
   PubMed Web of Science ®Google Scholar
• Fouladi M. Histone deacetylase inhibitors in cancer therapy. Cancer Invest. 2006;24(5):521–527.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Marcucci G, Parthun MR, et al. A Phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood. 2005;105(3):959–967.
   PubMed Web of Science ®Google Scholar
• Bates SE, Zhan Z, Steadman K, et al. Laboratory correlates for a Phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br J Haematol 2010;148(2):256–267.
   PubMed Web of Science ®Google Scholar
• Woo S, Gardner ER, Chen X, et al. Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res. 2009;15(4):1496–1503.
   PubMed Web of Science ®Google Scholar
• Shiraga T, Tozuka Z, Ishimura R, et al. Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes. Biol Pharm Bull. 2005;28(1):124–129.
   PubMed Web of Science ®Google Scholar
• Fehrenbach T, Cui Y, Faulstich H, et al. Characterization of the transport of the bicyclic peptide phalloidin by human hepatic transport proteins. Naunyn Schmiedebergs Arch Pharmacol. 2003;368(5):415–420.
   PubMed Web of Science ®Google Scholar
• Mann BS, Johnson JR, He K, et al. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res. 2007;13(8):2318–2322.
   PubMed Web of Science ®Google Scholar
• Prince HM, Bishton MJ, Harrison SJ. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res. 2009;15(12):3958–3969.
   PubMed Web of Science ®Google Scholar
• Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol. 2009;27(32):5459–5468.
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA, Yang LP. Romidepsin: a guide to its clinical use in cutaneous T-cell lymphoma. Am J Clin Dermatol. 2012;13(1):67–71.
   Web of Science ®Google Scholar
• O’Connor OA, Heaney ML, Schwartz L, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol. 2006;24(1):166–173.
   PubMed Web of Science ®Google Scholar
• Matsuoka H, Unami A, Fujimura T, et al. Mechanisms of HDAC inhibitor-induced thrombocytopenia. Eur JPharmacol. 2007;571(2–3):88–96.
   Web of Science ®Google Scholar
• Piekarz RL, Frye AR, Wright JJ, et al. Cardiac studies in patients treated with depsipeptide, FK228, in a Phase II trial for T-cell lymphoma. Clin Cancer Res. 2006;12(12):3762–3773.
   PubMed Web of Science ®Google Scholar
• Ritchie D, Piekarz RL, Blombery P, et al. Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report. Haematologica. 2009;94(11):1618–1622.
   PubMed Web of Science ®Google Scholar
• Ueda H, Nakajima H, Hori Y, et al. Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No 968, on Ha-ras transformed NIH3T3 cells. Biosci Biotechnol Biochem. 1994;58(9):1579–1583.
   Web of Science ®Google Scholar
• Khan SB, Maududi T, Barton K, et al. Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. Br J Haematol. 2004;125(2):156–161.
   PubMed Web of Science ®Google Scholar
• Xiao JJ, Foraker AB, Swaan PW, et al. Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1. J Pharmacol Exp Ther. 2005;313(1):268–276.
   PubMed Web of Science ®Google Scholar
• Page JG, Rodman LE, Heath JE, et al. Effect of infusion rate on toxicity of depsipeptide (NCS-63–176) in Beagle dogs. Proc Am Assoc Cancer Res. 1995;36;368:(Abstr 2193).
   Google Scholar
• Li Z, Chan KK. A subnanogram API LC/MS/MS quantitation method for depsipeptide FR901228 and its preclinical pharmacokinetics. J Pharm BiomedAnal. 2000;22(1):33–44.
   PubMed Web of Science ®Google Scholar
• Marshall JL, Rizvi N, Kauh J, et al. A Phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol. 2002;2(6):325–332.
   PubMedGoogle Scholar
• Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009;27(32):5410–5417.
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117(22):5827–5834.
   PubMed Web of Science ®Google Scholar
• Paoluzzi L, Scotto L, Marchi E, Zain J, Seshan VE, O’Connor OA. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma. Clin Cancer Res. 2010;16(2):554–565.
   PubMed Web of Science ®Google Scholar
• Marchi E, Kalac M, Bongero D, et al. Combination of Epigenetic Agents Synergistically Reverse the Malignant Phenotype in Models of T-Cell Lymphoma ASH Annual Meeting Abstracts 2011;118: 2727.
   Google Scholar